Evidence map›Paper›PMID 41069182›Full record

ArticleJournal of genetic counseling2025

Assessment of barriers to pancreatic cancer surveillance in high-risk individuals.

Grace G Snyder, Daniel Clay, Sara Karley, Samantha Pipito, Rebecca Mueller, Angela Bradbury, Kara Maxwell, Katherine L Nathanson, Mersedeh Rohanizadegan, Payal Shah and 3 more

Abstract read
In one paragraph

Article in Journal of genetic counseling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Grace G SnyderGenetic Counseling Program, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0009-0004-7781-5459
Daniel ClayDivision of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Sara KarleyDivision of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Samantha PipitoDivision of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Rebecca MuellerGenetic Counseling Program, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Angela BradburyDivision of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Kara MaxwellDivision of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Katherine L NathansonDivision of Translational Medicine and Human Genetics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Mersedeh RohanizadeganDivision of Translational Medicine and Human Genetics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Payal ShahDivision of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Susan M DomchekDivision of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Jessica M LongDivision of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0003-0382-7890
Bryson W KatonaDivision of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0001-8186-9119

Funding

Ann and Richard Frankel Fund for Pancreatic CancerBasser Center for BRCABerg Family BRCA Pancreatic Cancer Research FundSmith Family Pancreatic Cancer Research FundSusan and David Wolk Fund for Pancreatic Cancer Research
6 · The paper itself

Abstract

Individuals with increased familial or genetic risk of pancreatic cancer (PC) may be recommended to undergo regular PC surveillance. Genetic counselors are often involved in discussions about PC surveillance for high-risk individuals (HRIs); however, barriers to HRIs' participation in PC surveillance are not well characterized. This study aimed to identify reasons that HRIs cease, defer, or do not commence recommended PC surveillance through telephone interviews. Participants either had prior annual PC surveillance with no surveillance completion in ≥2 years, had a ≥2-year period without surveillance completion, or had not completed an initial surveillance imaging study 3 months after it was ordered. Fifty telephone interviews were analyzed using directed content analysis. Twenty interviewees had familial PC (34.5%) and 38 (65.5%) had a pathogenic variant associated with increased PC risk, with BRCA2 being the most common (N = 15, 25.9%). Interviewees were 74.1% women and 93.1% White with a median age of 63.0 years. Logistical barriers (N = 11, 34.4%), different healthcare professional recommendations (N = 9, 28.1%), other health issues (N = 8, 25.0%), and difficulty recalling surveillance recommendations (N = 8, 25.0%) were the top reasons for ceasing or deferring PC surveillance. Difficulty recalling surveillance recommendations (N = 5, 27.8%), cost (N = 4, 22.2%), and invasiveness of procedures (N = 4, 22.2%) were the top reasons for not commencing PC surveillance. Other reasons included the COVID-19 pandemic, moving from the service delivery area, cost, concerns about imaging studies, nonmedical life events, and fear. Several barriers identified in this study were consistent with barriers faced in screening for other more common cancers. These results demonstrate the need for targeted strategies to reduce PC surveillance barriers for HRIs. Furthermore, given that HRIs face multiple barriers to PC surveillance, it is important that cancer genetics professionals familiarize themselves with these barriers to reduce their impact and to facilitate recommended PC surveillance among HRIs.

Indexed as

Pancreatic NeoplasmsAdultAgedFemaleGenetic Predisposition to DiseaseHumansMaleMiddle Agedcancer genetic counselingcancer risk managementcontent analysishealth decisionspancreatic cancer surveillancepatient‐centered careservice delivery barriers

Identifiers

PMID41069182
PMCPMC12511838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.